Applicant, as named in the Orange Book
Esperion Theraps Inc
Next listed expiry: Nexletol on 19 Jun 2040. 2 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Nexletol NDA 211616 bempedoic acid | 19 Jun 2040 patent |
| Nexlizet NDA 211617 bempedoic acid; ezetimibe | 19 Jun 2040 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.